J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
August 13 2019 - 7:53AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
on Tuesday said the European Commission approved the use of
Imbruvica in two additional indications.
Janssen said Imbruvica is now approved in combination with
obinutuzumab in adults with previously untreated chronic
lymphocytic leukemia, and in combination with rituximab for adults
with Waldenstrom's macroglobulinemia, a rare and incurable type of
non-Hodgkin's lymphoma.
The European Medicines Agency's Committee for Medicinal Products
for Human Use in June recommended EC approval of the expanded use
of Imbruvica.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 13, 2019 07:38 ET (11:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
